The agency determined that domestic insulin companies with the advantages of production capacity scale, brand stickiness, and sales coverage are expected to clearly benefit.
The national insulin collection bid renewal announced the proposed selection results. All 13 companies participating in the collection won the bid, and 4 products lost the selection. The relevant companies were Novo Nordisk, Eli Lilly, and Jiangsu Wanbang.
CITIC Securities released a research report saying that the 2024 special insulin collection follow-up document was issued, and the current collection cycle is longer and the volume is higher; judging from the pricing rules, the new revival selection mechanism is relatively gentle; although the rules for determining the volume of this agreement are complicated, overall, enterprises are encouraged to be selected in Class A. Compared with the lowest winning bid price in the previous collection, there is some room for Class A selection price, and there is a large proportion of potential B/C redistribution amount.
The agency determined that domestic insulin companies with the advantages of production capacity scale, brand stickiness, and sales coverage are expected to clearly benefit.
Insulin-related companies:
Federal Pharmaceuticals (03933): At the national insulin collection and renewal site this morning, Federal Pharmaceuticals declared a total of six products, and reported a price of 65.31 yuan/tube for insulin glargine injections; human insulin injections, arginine human insulin injections, arginine human insulin mixed injections, Menthong insulin injections, and Menthong insulin 30 injections all reported a price of 25.91 yuan/stick.